Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

Pre-specified analysis (n=4,304) found the effect of dapaglifozin on the primary outcome (sustained eGFR decline ≥50%, end-stage kidney disease, or kidney or cardiovascular death) did not vary according to the patient’s baseline glycaemic status.

Source:

Diabetes Care